Another Study Shows Fenofibrate Benefit on Diabetic Retinopathy Another Study Shows Fenofibrate Benefit on Diabetic Retinopathy
While a Korean study shows reduction in diabetic retinopathy progression by 11% with fenofibrate plus statin compared with statin alone, some reservations remain over wider use.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 23, 2022 Category: Drugs & Pharmacology Tags: Ophthalmology News Source Type: news
More Evidence That Fenofibrate Slows Diabetic Eye Disease
(MedPage Today) -- Use of the cholesterol-lowering drug fenofibrate had a modest but statistically significant association with reduced risk of vision-threatening diabetic retinopathy (VTDR), according to results of a large multicenter cohort study... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - April 26, 2022 Category: Endocrinology Source Type: news
' Exciting' Findings on Fenofibrate in Diabetic Retinopathy'Exciting' Findings on Fenofibrate in Diabetic Retinopathy
People with diabetic retinopathy who took the cholesterol-lowering drug fenofibrate were less likely to progress to vision-threatening forms of the disease, in a large database study.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 7, 2022 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
fenofibrate
Title: fenofibrateCategory: MedicationsCreated: 3/30/2022 12:00:00 AMLast Editorial Review: 3/30/2022 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - March 30, 2022 Category: Cardiology Source Type: news
Drug used to reduce blood fats may cut SARS-CoV-2 infection by 70 per cent: Study
The team led by researchers from the University of Birmingham in the UK found that fenofibrate and its active form fenofibric acid can significantly reduce SARS-COV-2 infection, that causes COVID-19, in human cells in the laboratory. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 6, 2021 Category: Pharmaceuticals Source Type: news
Drug used to treat high cholesterol can reduce number of COVID-19-infected cells by up to 70%
Fenofibrate, a drug used to treat high cholesterol, may be able to treat COVID-19, according to a study from researchers at the University of Birmingham and Keele University. (Source: the Mail online | Health)
Source: the Mail online | Health - August 5, 2021 Category: Consumer Health News Source Type: news
Fenofibrate Delays Dialysis Need and Reduces CV Risk in CKD Fenofibrate Delays Dialysis Need and Reduces CV Risk in CKD
A new study examines the beneficial effects of fenofibrate in reducing CV risk and dialysis need among advanced CKD patients.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 28, 2021 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news
Promising clinical data for fenofibrate's ability to prevent lung damage in COVID patients
(The Hebrew University of Jerusalem) In what has the potential to significantly change how Corona patients are being treated and the severity of the disease, research spearheaded at Jerusalem's Hebrew University gathered early clinical evidence demonstrating the efficacy of an existing drug in treating COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 22, 2020 Category: Infectious Diseases Source Type: news
Alembic Pharma gets USFDA nod for cholesterol lowering drug
In a regulatory filing, Alembic Pharma said "it has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Fenofibrate capsules USP in the strengths of 67 mg, 134 mg and 200 mg. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 21, 2020 Category: Pharmaceuticals Source Type: news
ASN: Aggressive Control of BP, Lipids in T2DM May Up Kidney Risk
THURSDAY, Nov. 1, 2018 -- Intensive blood pressure (BP) control and fenofibrate use in patients with type 2 diabetes who are at high risk for cardiovascular disease may increase the risk for adverse kidney events, according to a study published in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 1, 2018 Category: Pharmaceuticals Source Type: news
Lipofen (Fenofibrate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 4, 2018 Category: Drugs & Pharmacology Source Type: news
Triglide (Fenofibrate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2017 Category: Drugs & Pharmacology Source Type: news
Fenoglide (Fenofibrate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2017 Category: Drugs & Pharmacology Source Type: news
Antara (Fenofibrate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2017 Category: Drugs & Pharmacology Source Type: news
Fenofibrate may reduce heart disease risk in some patients with type 2 diabetes
A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of ' good ' cholesterol, despite being treated with statins. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 28, 2016 Category: Science Source Type: news
